Nizatidine

Nizatidine

File:Nizatidine.png
Clinical data
License data	US FDA: Nizatidine
Pregnancy category	AU: B3
Routes of administration	Oral
ATC code	A02BA04 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	>70%
Protein binding	35%
Metabolism	Hepatic
Elimination half-life	1-2 hours
Excretion	Renal
Identifiers
IUPAC name N-[2-(2-dimethylaminomethylthiazol- 4-ylmethylthio)ethyl]-N'-methyl- 2-nitrovinylidenediamine
CAS Number	76963-41-2
PubChem CID	3033637
DrugBank	APRD00706
CompTox Dashboard (EPA)	DTXSID5023376
ECHA InfoCard	100.155.683
Chemical and physical data
Formula	C12H21N5O2S2
Molar mass	331.46 g/mol

Nizatidine is a histamine H₂-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.

Clinical use

Main article: H2-receptor antagonist

Certain preparations of nizatadine are now available over the counter in various countries including the United States.

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.

Nazitidine proved to be the last new histamine H₂-receptor antagonists introduced prior to the advent of proton pump inhibitors.